

Lansing, MI, June 10, 2016 – GreenMark Biomedical Inc. today announced an agreement relating to the transfer of certain intellectual property from EcoSynthetix Inc. (TSX: ECO), a renewable chemicals company that produces a portfolio of biobased products. GreenMark, a Delaware start-up corporation with facilities in Michigan, was formed for the purpose of delivering health benefits to society through biobased targeting technologies. The company will be developing and commercializing a platform of diagnostic and therapeutic technologies using biobased, nano-scale targeting particles.

GreenMark's technology has application opportunities in dentistry and medicine, including targeting therapies for cancer treatment. The new venture involves a team of recognized leaders in oncology, dentistry, health care, polymer science and successful business ventures. GreenMark intends to maintain a strong partner relationship with EcoSynthetix as a supplier of the biobased nanoparticles to GreenMark's proprietary applications. The foundational EcoSynthetix technology is industrially and commercially proven and has been in the market since 2006.

Dr. Steven Bloembergen co-founded EcoSynthetix in 1996 with a vision to reduce our reliance on petroleum-based products, and helped develop the technology and multidisciplinary team that grew this renewable chemicals company into a global corporation. In his role as Executive VP Technology he created a collaboration network with US and Canadian universities involving industrial and health based technologies supported by government grants. This network resulted in the foundational technology for GreenMark.

"We are desperate for new and safe delivery technologies and I am very pleased to be a part of this new venture and excited to help facilitate what I feel is of critical importance to our fight against cancer", said Dr. Kenneth J. Pienta, MD, professor of Urology at the Brady Urological Institute and the Departments of Oncology, Pharmacology, Molecular Sciences, Cellular and Molecular Medicine and Pathobiology at the Johns Hopkins School of Medicine.

"I look forward to playing part in the success of a company with truly innovative concepts and will enjoy seeing this through to 'real world' commercial applications", said Dr. Joerg Lahann, Ph.D., expert in smart materials and Director of the Biointerfaces Institute and professor of Chemical Engineering, Materials Science & Engineering and Biomedical Engineering at the University of Michigan. *"I view this as a breakthrough opportunity in the diagnosis and treatment of dental caries and foresee many other applications",* added Dr. Brian Clarkson, B.Ch.D., L.D.S., M.S., Ph.D., Professor, Department of Cariology, Restorative Sciences and Endodontics, University of Michigan School of Dentistry.

"We are excited to see this very impressive team of people who have been working on the medical technology since early 2000 come together to form GreenMark, bringing focus and expertise to leverage some of our core technology into these exciting biomedical fields. In particular we look forward to a continued partnership with our co-founder Dr. Bloembergen through future supply to GreenMark and through his continued advisory support to EcoSynthetix", said Jeff MacDonald, CEO of EcoSynthetix.

Bloembergen is transitioning to his role as Chairman and CEO of this new venture in June 2016. *"We will aim to be patient for growth but impatient for revenue as we drive our shorter term dental and longer term medical technologies to commercial success",* explained Bloembergen.

About GreenMark Biomedical Inc. (<http://greenmark.bio>)

GreenMark's central concept is the biodelivery of health solutions on target, precisely where they are needed. The company has patented, patent-pending and proprietary technologies that use different grades of biobased nanoparticles uniquely modified into novel products that have built-in targeting performance for diagnostic and therapeutic medical and dental applications.

GreenMark Biomedical Inc., 3815 Technology Boulevard, Lansing, MI 48910, USA.

Contact: info@greenmark.bio or (517) 336-4665.

About EcoSynthetix Inc. (www.ecosynthetix.com)

EcoSynthetix offers a range of engineered biopolymers that replace the non-renewable chemicals used to manufacture many products, such as paper and packaging, personal care products, insulation and wood composites. The Company's flagship products, EcoSphere® biolatex® and DuraBind™ biopolymers, provide a sustainable alternative that reduces a customer's carbon footprint, decreases overall material costs and improves performance. The Company is publicly traded on the Toronto Stock Exchange (TSX: ECO).

Forward-Looking Statements

Certain statements in this Press Release constitute "forward-looking" statements that involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, objectives or achievements of the Company, or industry results, to be materially different from any future results, performance, objectives or achievements expressed or implied by such forward looking statements. The forward-looking statements in this Press Release include, but are not limited to, statements regarding the Company's expected product pipeline, plans to expand the Company's business into new markets, the Company's ability to achieve organizational efficiencies, and other statements regarding the Company's plans and expectations in 2016. These statements reflect our current views regarding future events and operating performance and are based on information currently available to us, and speak only as of the date of this Press Release. These forward-looking statements involve a number of risks, uncertainties and assumptions and should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether or not such performance or results will be achieved. Those assumptions and risks include, but are not limited to, the Company's ability to successfully allocate capital as needed and to develop new products, as well as the fact that our results of operations and business outlook are subject to significant risk, volatility and uncertainty. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including the factors identified in the "Risk Factors" section of the Company's Annual Information Form dated March 31, 2015. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described in this Press Release as intended, planned, anticipated, believed, estimated or expected. Unless required by applicable securities law, we do not intend and do not assume any obligation to update these forward-looking statements.